Oncolytics Biotech Inc. (ONCY)
| Market Cap | 103.34M +121.3% |
| Revenue (ttm) | n/a |
| Net Income | -28.76M |
| EPS | -0.30 |
| Shares Out | 116.13M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 633,775 |
| Open | 0.8900 |
| Previous Close | 0.9000 |
| Day's Range | 0.8721 - 0.9019 |
| 52-Week Range | 0.3258 - 1.5100 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 7.33 (+723.69%) |
| Earnings Date | May 22, 2026 |
About ONCY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ONCY stock is "Strong Buy." The 12-month stock price target is $7.33, which is an increase of 723.69% from the latest price.
News
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-M...
Oncolytics says in alignment with FDA following pelareorep Type C meeting
Oncolytics (ONCY) announced that a Type C meeting with the FDA has resulted in alignment on the design of a pivotal clinical study to support approval of pelareorep in patients
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient ...
Oncolytics price target lowered to $5 from $7 at Lake Street
Lake Street analyst Chad Messer lowered the firm’s price target on Oncolytics (ONCY) to $5 from $7 and keeps a Buy rating on the shares after the company reported FY25
Oncolytics schedules FDA meeting for pelareorep registrational path
Oncolytics (ONCY) announced it has scheduled a Type C meeting with the FDA on April 16, to discuss a potential registrational development path for pelareorep in anal cancer. “We believe
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational,...
Oncolytics completes domicile change to the U.S.
Oncolytics (ONCY) announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province of Alberta in Canada to the State of Nevada in
Oncolytics Biotech® Completes Domicile Change to the United States
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the...
Oncolytics files $250M mixed securities shelf
06:07 EDT Oncolytics (ONCY) files $250M mixed securities shelf
Oncolytics to present new data on Pelareorep at AACR 2026
The company states: “Oncolytics (ONCY) Biotech announced two abstracts across distinct tumor types were accepted for presentation at the American Association for Cancer Research – AACR – Annual Meetin...
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS...
Oncolytics initiates randomized colorectal cancer study
Oncolytics (ONCY) Biotech announced the initiation of a metastatic colorectal cancer, mCRC, Phase 2 study that will be referred to as REO 033. In this trial, second-line RAS-mutated, microsatellite-st...
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRA...
Oncolytics concludes enrollment in GOBLET study
Oncolytics (ONCY) Biotech(R) announced that it has concluded enrollment in the GOBLET study, having generated the necessary clinical and translational data to inform its next phase of development. Wit...
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate ma...
Oncolytics receives FDA Fast Track Designation for pelareorep
Oncolytics (ONCY) Biotech announced that the U.S. Food and Drug Administration has granted Fast Track Designation to pelareorep in combination with bevacizumab and leucovorin, fluorouracil, irinotecan...
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the ...
Oncolytics Biotech Transcript: AGM 2026
The meeting approved the Continuance and Domestication Resolutions by a two-thirds majority and the 2026 Incentive Award Plan by a majority, with no questions raised on any motions. Voting procedures and shareholder participation were clearly outlined.
Oncolytics appoints John McAdory as EVP, strategy and operations
Oncolytics Biotech (ONCY) announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. McAdory will oversee c...
Oncolytics announces updates data from GOBLET cohort 4
Oncolytics (ONCY) Biotech announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous cell anal carcinoma, SCAC, a setting with no U.S. Food and Drug Administr...
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no appr...
Oncolytics outlines strategic rationale for proposal to change jurisdiction
Oncolytics (ONCY) Biotech provided additional context regarding its previously announced proposal to change the Company’s jurisdiction of incorporation from Alberta, Canada, to the State of Nevada in ...
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided addit...
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the statu...